» » »

Treatment of Pancreatic Cancer Fresno CA

Inhibiting the action of an enzyme called TAK-1 reverses pancreatic cancer resistance to chemotherapy, a finding that could lead to the development of a new way to treat the disease, researchers say. Pancreatic cancer is resistant to every currently available anti-cancer treatment.

Gene Raymond Conley, MD
(559) 228-5366
2615 E Clinton Ave
Fresno, CA
Specialties
Urology, Internal Medicine
Gender
Male
Education
Medical School: Loma Linda Univ Sch Of Med, Loma Linda Ca 92350
Graduation Year: 1976
Hospital
Hospital: V A Central California, Fresno, Ca; Fresno Comm Med Ctr, Fresno, Ca

Data Provided by:
Jacob Tarjoman
(559) 225-6100
2615 E Clinton Ave
Fresno, CA
Specialty
Urology

Data Provided by:
Jacob Tarjoman, MD
(559) 225-6100
Va Medicine Center Department Urol 2615 East Clint
Fresno, CA
Specialties
Urology
Gender
Male
Education
Medical School: Teheran Univ, Fac Of Med, Teheran, Iran
Graduation Year: 1956

Data Provided by:
Thomas X Minor
(559) 438-2777
6113 N Fresno St
Fresno, CA
Specialty
Urology

Data Provided by:
Devonna Mae Kaji, MD
(559) 353-6195
6712 N Van Ness Blvd
Fresno, CA
Specialties
Urology
Gender
Female
Education
Medical School: Univ Of Hi John A Burns Sch Of Med, Honolulu Hi 96822
Graduation Year: 1984

Data Provided by:
Gary A Storey
(559) 228-5366
2615 E Clinton Ave
Fresno, CA
Specialty
Urology

Data Provided by:
Gary Albert Storey, MD
(559) 431-7660
2615 E Clinton Ave
Fresno, CA
Specialties
Urology
Gender
Male
Education
Medical School: Washington Univ Sch Of Med, St Louis Mo 63110
Graduation Year: 1961

Data Provided by:
Harold Greg Rainwater
(559) 438-2777
6113 N Fresno St # 101
Fresno, CA
Specialty
Urology

Data Provided by:
Robert J Deklotz, MD FACS
(559) 431-1410
2220 W Dovewood Ln
Fresno, CA
Gender
Male
Education
Medical School: Kansas
Graduation Year: 1959

Data Provided by:
Howard Marshall Price, MD
(559) 439-0678
7510 N Tahan Ave
Fresno, CA
Specialties
Urology
Gender
Male
Languages
French, Spanish
Education
Medical School: Stanford Univ Sch Of Med, Stanford Ca 94305
Graduation Year: 1983
Hospital
Hospital: Milford-Whittinsville Regional, Milford, Ma
Group Practice: Umass Memorial Medical Group

Data Provided by:
Data Provided by:

Treatment of Pancreatic Cancer

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- Inhibiting the action of an enzyme called TAK-1 reverses pancreatic cancer resistance to chemotherapy, a finding that could lead to the development of a new way to treat the disease, researchers say.

Pancreatic cancer is resistant to every currently available anti-cancer treatment.

"During the past few years we have been studying the role played by a cytokine or regulatory protein called transforming growth factor-beta [TGFbeta] in the development of pancreatic cancer. Recently we focused our attention on a unique enzyme activated by TGFbeta, TAK-1, as a mediator for this extreme drug resistance" in pancreatic cancer, study author Dr. Davide Melisi said in a news release from the European Cancer Organization.

He and his colleagues developed a TAK-1 inhibitor and tested it on its own and in combination with the anti-cancer drugs gemcitabine, oxaliplatin and SN-38 (a metabolite of the anti-cancer drug irinotecan) in pancreatic cancer cell lines. They also tested the TAK-1 inhibitor combined with gemcitabine against pancreatic cancer in mice.

"The use of this TAK-1 inhibitor increased the sensitivity of pancreatic cells to all three chemotherapeutic drugs," Melisi said.

"By combining it with classic anti-cancer drugs, we were able to use doses of drugs up to 70 times lower in comparison with the control to kill the same number of cancer cells. In mice, we were able to reduce significantly the tumor volume, to prolong the mice survival, and to reduce the toxicity by combining the TAK-1 inhibitor with very low doses of a classic chemotherapeutic drug, gemcitabine, that would have been ineffective otherwise," Melisi added.

The study was scheduled for presentation Sept. 24 at the joint meeting of the European Cancer Organization and the European Society for Medical Oncology in Berlin.

"This is the first time that TAK-1 has been indicated as a relevant target for the treatment of a solid tumor and that it is a valid approach to reverting the intrinsic drug resistance of pancreatic cancer," Melisi stated. "The TAK-1 inhibitor used in this study is an exciting drug that warrants further development for the treatment of pancreatic cancer."

More information

The American Cancer Society has more about pancreatic cancer.

SOURCE: European Cancer Organization, news release, Sept. 24, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com